Methods of treating leukemia
AssigneeShire BioChem Inc.
InventorsJacques Jolivet, Francis Giles, Hagop Kantarjian
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel method for treating leukemia in a host that has been previously treated with a Bcr-Abl tyrosine kinase inhibitor comprising administering to the host a therapeutically effective amount of a compound having the formula I: wherein B is cytosine or 5-fluorocytosine and R is selected from H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, and and where in each Rc is independently selected from the group comprising H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl an hydroxy protecting group.
Claims31
A method for treating a patient with leukemia comprising administering to a patient that has been previously treated with a Bcr-Abl tyrosine kinase inhibitor a therapeutically effective amount of a compound having the formula I:
- wherein B is cytosine or 5-fluorocytosine and R is selected from H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, and
- wherein each Rc is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and an hydroxy protecting group.
A method for treating a patient with leukemia comprising administering to a patient that has been previously treated with imatinib mesylate (STI-571) and has become resistant to the imatinib mesylate (STI-571) treatment, a therapeutically effective amount of a compound having the formula I:
- wherein B is cytosine or 5-fluorocytosine and R is selected from H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, and
- wherein each Rc is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and an hydroxy protecting group.
A method for treating leukemia in a patient comprising administering to a patient that has been previously treated with a Bcr-Abl tyrosine kinase inhibitor a therapeutically effective amount of at least one compound of general formula I
- wherein B is cytosine or 5-fluorocytosine and R is selected from H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-4 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, and
- wherein each Rc is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and an hydroxy protecting group, and at least one further therapeutic agent selected from nucleoside analogues, chemotherpeutic agents, multidrug resistance reversing agents and biological response modifiers.
Dependencies are inferred from the claim text.